CTCM Round 2 Expressions of Interest are NOW CLOSED
The Clinical Translation and Commercialisation Medtech (CTCM) program, delivered by MTPConnect, is offered under the 2020 Early Stage Translation and Commercialisation Support Grant of the Medical Research Future Fund's Medical Research Commercialisation Initiative.
The CTCM program can provide between $250,000 and $1.5 million to SMEs to support early clinical development of medical devices with commercial potential. SMEs are defined as having 199 employees or less.
Projects must focus on the development of a medical device for human use, the purpose of which is to diagnose, prevent, monitor, treat or alleviate a disease or injury, or modify or monitor anatomy or physiological functions of the body.
Funding will only be awarded to projects where the device's capability has already been validated with research and/or preclinical studies.
Eligible applications must include some level of innovation in hardware (proposals relating to pure software as a medical device (SaMD) are ineligible).
The project term for funded CTCM Projects is a maximum of 24-months. To be eligible, applicants are required to provide a co-contribution dependent on the total CTCM funding requested. Additional in-kind or cash contributions above this threshold will be viewed favourably.
Applications for CTCM Round 2 funding CLOSED on Friday 7 October 2022 at 16:00 AEDT.
An Information Session was held online AND in-person at QIMR Berghofer in Brisbane on Tuesday 23 August 2022 - Please view recording at the bottom of this page. You can also listen a podcast version of the information session.
In the recording you will hear from MTPConnect and CTCM Partners:
- Dr Duncan Macinnis, Director of Stakeholder Engagement (NSW and ACT)
- Stuart Anderson, CTCM Program Manager, MTAA
- Dr Andrew Milligan, MedTech Venture Case Manager, MDPP
- Hebbat Manhy, Head of Technology, Cicada Innovations
For some tips on preparing your application, view the on-demand webinar on our website 'Show Me The Money: Preparing Successful Commercialisation Funding Applications (18 Nov 2020)'.